Biotechnology
Jacobio Completes First Patient Dosage of Aurora A Inhibitor JAB-2485 in U.S
BEIJING and SHANGHAI and BOSTON, Jan. 8, 2023 /PRNewswire/ -- Jacobio Pharma (1167.HK) announced it has completedthe first patient dosage of its in-house R&D drug candidate Aurora A Inhibitor JAB-2485 in a Phase I/IIa clinical trial for advanced solid tumour patients in U.S. JAB-2485 is a high...
2023-01-08 14:17
3395
Fosun Pharma and Henlius Entered into an Exclusive License Agreement for Serplulimab in the US
PRINCETON, N.J., Jan. 7, 2023 /PRNewswire/ -- Fosun Pharma (600196.SH, 02196.HK) has recently entered into an exclusive license agreement with Shanghai Henlius Biotech, Inc. (2696.HK) for the commercialisation of Henlius independently developed anti-PD-1 monoclonal antibody (mAb) serplulimab inth...
2023-01-07 17:29
3746
Ocedurenone (KBP-5074) Featured at ASN Kidney Week: Ocedurenone is a Potential New Treatment Option for Patients with Uncontrolled or Resistant Hypertension and Advanced CKD
Hepatic Impairment and Drug-Drug Interaction Study Results Presented PRINCETON, N.J., Jan. 6, 2023 /PRNewswire/ -- KBP Biosciences PTE. Ltd. ("KBP Biosciences" or the "Company"), a clinical-stage biotechnology company dedicated to research, development, and commercialization of innovative medici...
2023-01-06 21:00
2027
Double-blind period completes! Primary endpoint analysis of phase 3 clinical trial to be conducted for China's first hormone replacement treatment targeting hypoparathyroidism
Submission of NDA to the NMPA is planned within 2023 at the earliest SHANGHAI, Jan. 6, 2023 /PRNewswire/ -- VISEN Pharmaceuticals, an innovative biopharmaceutical company focused on endocrine diseases, announced today that it has completed the double-blind period of PaTHway China Trial, a phase 3...
2023-01-06 18:00
1609
SK Biopharmaceuticals CEO Donghoon Lee Buys 3,000 Shares of Company Stock
- CEO shows commitment and confidence in the company's future through share purchase PANGYO, South Korea, Jan. 5, 2023 /PRNewswire/ -- SK Biopharmaceuticals, an innovative global pharmaceutical company, today announced that Mr.Donghoon Lee, the Chief Executive Officer and President of SK Biophar...
2023-01-06 09:10
1541
Duality Biologics Announces License Agreement of its Next-generation ADC platform with Adcendo
* Duality to grant license of DITAC (Duality Immune Toxin Antibody Conjugates) platform to Adcendo for its lead uPARAP ADC program * Duality to receive upfront payment, development, regulatory and commercial milestones, and tiered royalties * Collaboration based on synergies between Adcendo ...
2023-01-05 09:00
1294
Ascentage Pharma to Present at the 41st Annual J.P. Morgan Healthcare Conference
SUZHOU, China and ROCKVILLE, Md., Jan. 4, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that its Chairman and CEO, Dr.Dajun Yang, has accep...
2023-01-05 09:00
2367
Innovent to Present at 41st Annual J.P. Morgan Healthcare Conference
ROCKVILLE, Md. and SUZHOU, China, Jan. 4, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", "the Company") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, o...
2023-01-05 00:00
2758
OnCusp Therapeutics Announces Appointment of Robert Forrester and Chau Khuong to Board of Directors
NEW YORK, Jan. 4, 2023 /PRNewswire/ -- OnCusp Therapeutics, a global biotechnology company with deep translational and clinical development expertise in oncology therapeutics, today announced the appointment of serial entrepreneurRobert Forrester and venture capitalist Chau Khuong as independent ...
2023-01-04 21:00
1960
Alterity Therapeutics to Participate in the Sachs Associates 6th Annual Neuroscience Innovation Forum
MELBOURNE, Australia and SAN FRANCISCO, Jan. 3, 2023 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced thatDavid Stamler, M.D., ...
2023-01-03 23:25
1623
Burning Rock Received FDA Breakthrough Device Designation for its OverC™ Multi-Cancer Detection Blood Test
IRVINE, Calif., Jan. 3, 2023 /PRNewswire/ -- Burning Rock (NASDAQ/LSE: BNR), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that its OverC™ Multi-Cancer Detection Blood Test (MCDBT) has been granted Breakthro...
2023-01-03 22:24
1004
Bridge Biotherapeutics to Present at BIOTECH SHOWCASE™ 2023
SAN FRANCISCO and SEONGNAM, South Korea, Jan. 3, 2023 /PRNewswire/ -- Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotech company developing novel drugs for cancer, fibrosis and inflammation, announced that the company is presenting at Biotech Showcase™ 2023. Pavel Printsev,...
2023-01-03 22:00
1223
ProfoundBio Announces Initiation of First-in-Human Trial for PRO1184, a Folate Receptor Alpha-Directed ADC with a Topoisomerase 1 Inhibitor Payload, and Receives FDA "Study May Proceed" Letter for PRO1160, a CD70-Directed ADC
* PRO1184 first-in human study initiated and first patients dosed * PRO1160 first-in-human study cleared for initiation in the US * Both PRO1184 and PRO1160 are based on a novel, proprietary, and internally developed linker-drug technology platform SUZHOU, China and WOODINVILLE, Wash., Jan. ...
2023-01-03 20:00
2488
Antengene to Present at the 41st Annual J.P. Morgan Healthcare Conference
SHANGHAI and HONG KONG, Jan. 3, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hema...
2023-01-03 14:10
1892
Complete Genomics to Present its Multiple, Innovative Sequencing Platforms at BIOTECH SHOWCASE™ 2023
Enhanced sequencing capabilities offer opportunity to accelerate breakthroughs in life science research SAN JOSE, Calif., Dec. 29, 2022 /PRNewswire/ -- Complete Genomics Inc（https://completegenomics.mgiamericas.com/）, a subsidiary of MGI Tech Co., Ltd., today announced that it is presenting...
2022-12-30 01:58
2273
Alterity Therapeutics Announces Allowance of New Composition of Matter Patent by the United States Patent and Trademark Office
- Patent covers more than 100 novel compounds targeting neurodegenerative diseases including Parkinson's and Alzheimer's - MELBOURNE, Australia and SAN FRANCISCO, Dec. 29, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company d...
2022-12-29 23:25
2633
GeneQuantum and WuXi XDC Entered into Strategic Collaboration to Empower Innovative Bioconjugate Development
SUZHOU, China, Dec. 26, 2022 /PRNewswire/ -- GeneQuantum Healthcare (GQ), a global innovative biotechnology company dedicated to the development of the next generation bioconjugate drugs , and WuXi XDC, a leading global Contract Research, Development and Manufacturing Organization (CRDMO), ann...
2022-12-26 23:01
2706
CJ CheilJedang, and Emmyon, Inc. sign a Licensing Agreement to commercialize a dietary supplement with natural extracts for use in significant improvement of skeletal muscle mass and function in humans.
SEOUL, South Korea and ROCHESTER, Minn., Dec. 26, 2022 /PRNewswire/ -- CJ Food and Nutrition Tech (CJ FNT), a newly formed business unit of CJ CheilJedang, a South Korea based global food and nutrition company, and Emmyon, Inc., a privately-held biotechnology start-up company based inRochester, MN...
2022-12-26 21:00
2998
Nuevocor to Present at Biotech Showcase during JPM week and at Keystone Symposium on Heart Development and Disease
SINGAPORE, Dec. 21, 2022 /PRNewswire/ -- Nuevocor
2022-12-21 22:00
2306
QureBio Ltd. to Present its Q-1802 Clinical Phase Ⅰ Data at 2023 ASCO-GI Meetings
SHANGHAI, Dec. 20, 2022 /PRNewswire/ -- QureBio Ltd., a clinical-stage biopharmaceutical company focusing on development of bispecific antibodies and other engineeredBiopharmaceuticals for the treatment of cancer, inflammation, and other serious disorders, today announced that Phase Ⅰ Clinical D...
2022-12-21 10:30
2336
Week's Top Stories
Most Reposted
Alpha Trading Cup 2024 Award Night: Top Trader Achieves Remarkable 315% Profit, as Over 1,149 Competitors Vie for USD 44,000 Prize Pool
[Picked up by 313 media titles]
2024-10-25 18:29
International Golo Mori Jazz 2024: Experience the Harmony of Eastern Indonesia's Exotic Beauty and Romantic Jazz Music
[Picked up by 300 media titles]
2024-10-25 22:48
2024 Malaysia E-commerce Product Selection Expo Reaches Major Milestone Attracting Leading Brands and Businesses From China
[Picked up by 300 media titles]
2024-10-25 07:00
RuggON Showcases Latest Mining Technology at IMARC 2024
[Picked up by 294 media titles]
2024-10-28 14:32
TotalEnergies ENEOS Completes a 1.8 MWp Floating Solar Photovoltaic System Project, a Second Collaboration with S. Kijchai Enterprise in Thailand
[Picked up by 288 media titles]
2024-10-29 11:24
Most Read
Alpha Trading Cup 2024 Award Night: Top Trader Achieves Remarkable 315% Profit, as Over 1,149 Competitors Vie for USD 44,000 Prize Pool
2024-10-25 18:29
8605
International Golo Mori Jazz 2024: Experience the Harmony of Eastern Indonesia's Exotic Beauty and Romantic Jazz Music
2024-10-25 22:48
7453
Infobip and Singtel Partner to Advance Customer Engagement for Singapore Businesses with Rich Communication Services
2024-10-25 12:30
7037
Global development relies on cooperation
2024-10-25 12:38
6033
Peak Energy CEO Gavin Adda Speaks at Asia Clean Energy Summit 2024
2024-10-25 18:30
5741
